Conclusion
There is a substantial increase in the concentrations of PGE2 as PD progresses. Since PGE2 levels in GCF are positively correlated with gingival index, plaque index, probing pocket depths and clinical attachment levels, PGE2 may be considered as a Novel Biomarker in PD progression. However, controlled, longitudinal studies are needed to confirm this possibility.
Methods
A periodontal examination and collection of GCF by extracrevicular method was performed in 25 subjects selected randomly and categorized into three groups on the basis of plaque index, gingival index, probing pocket depth and clinical attachment level. Group I (healthy) consists of 10 subjects, Group II (chronic periodontitis) consists of 15 patients and Group III (after treatment group) consists of 15 patients of Group II. PGE2 levels were estimated in GCF samples by using the enzyme linked immunosorbent assay.
Results
All clinical parameters improved significantly after therapy (P < 0.001). PGE2 was detected in all the samples. Highest mean PGE2 concentrations in GCF were obtained for Group II while the lowest concentrations were seen in Group I and Group III. Statistically significant difference was found between the levels of PGE2 at Group-II and Group-III (P < 0.05).